Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis
- PMID: 11879135
- DOI: 10.1001/archopht.120.3.320
Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis
Abstract
Objective: To report the visual outcome in patients with a neovascular membrane (NVM) associated with idiopathic juxtafoveolar telangiectasis (IJFT).
Methods: We performed a retrospective, noncomparative analysis of 26 eyes of 16 patients with an NVM associated with bilateral IJFT (Gass classification group 2A). Eyes were divided into 2 groups: group WO (n = 11) included eyes with IJFT without evidence of an NVM on initial examination; eyes in group W (n = 15) had an NVM at the initial diagnosis of IJFT. In group WO, the initial visual acuity and the time between the initial examination to the diagnosis of an NVM were evaluated. Characteristic fundus findings, including the presence or absence of a chorioretinal anastomosis, intraretinal pigmentary plaques, and crystalline deposits, as well as the final visual acuity were reviewed for both groups.
Results: The initial visual acuity for eyes in group WO ranged from 20/20 to 20/70 (median, 20/30); in group W, from 20/20 to 4/200 (median, 20/70). The average time from initial diagnosis of IJFT to the development of an NVM was 73 months (range, 5-142 months). In group WO, chorioretinal anastomosis and concurrent perivascular retinal pigment epithelial hyperplasia were observed before the development of an NVM. The final visual acuity for all eyes ranged from 20/40 to 2/200 (median, 20/200). Eighty-one percent of eyes (21/26) had a final visual acuity of 20/200 or worse.
Conclusions: The stable final visual acuity in patients with an NVM associated with IJFT is generally poor, with 80% of eyes in this series having a final visual acuity of l20/200 or worse. In patients with IJFT, the presence of a chorioretinal anastomosis and retinal pigment epithelial hyperplastic plaques always preceded the development of an NVM.
Comment in
-
Chorioretinal anastomosis probably occurs infrequently in type 2A idiopathic juxtafoveolar retinal telangiectasis.Arch Ophthalmol. 2003 Sep;121(9):1345-6. doi: 10.1001/archopht.121.9.1345-b. Arch Ophthalmol. 2003. PMID: 12963631 No abstract available.
Similar articles
-
Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis.Am J Ophthalmol. 2004 Jul;138(1):147-9. doi: 10.1016/j.ajo.2004.01.047. Am J Ophthalmol. 2004. PMID: 15234300
-
Chorioretinal anastomosis probably occurs infrequently in type 2A idiopathic juxtafoveolar retinal telangiectasis.Arch Ophthalmol. 2003 Sep;121(9):1345-6. doi: 10.1001/archopht.121.9.1345-b. Arch Ophthalmol. 2003. PMID: 12963631 No abstract available.
-
Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis.Can J Ophthalmol. 2006 Feb;41(1):34-7. doi: 10.1016/S0008-4182(06)80063-3. Can J Ophthalmol. 2006. PMID: 16462869
-
Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2).Surv Ophthalmol. 2013 Nov-Dec;58(6):536-59. doi: 10.1016/j.survophthal.2012.11.007. Surv Ophthalmol. 2013. PMID: 24160729 Review.
-
Idiopathic juxtafoveal retinal telangiectasis: case report and literature review.Optometry. 2001 Apr;72(4):228-33. Optometry. 2001. PMID: 11338447 Review.
Cited by
-
A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.Clin Interv Aging. 2009;4:63-5. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503767 Free PMC article.
-
Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum.Graefes Arch Clin Exp Ophthalmol. 2007 Apr;245(4):612-5. doi: 10.1007/s00417-006-0402-7. Epub 2006 Sep 19. Graefes Arch Clin Exp Ophthalmol. 2007. PMID: 16988836
-
Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):619-21. doi: 10.1007/s00417-007-0732-0. Epub 2008 Jan 12. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 18193448
-
Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.Int Ophthalmol. 2019 Oct;39(10):2245-2256. doi: 10.1007/s10792-018-01060-x. Epub 2019 Jan 3. Int Ophthalmol. 2019. PMID: 30607862
-
Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2.Middle East Afr J Ophthalmol. 2016 Apr-Jun;23(2):222-4. doi: 10.4103/0974-9233.171773. Middle East Afr J Ophthalmol. 2016. PMID: 27162458 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources